Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.57 |
| ▸ | MAOB | P27338 | 7/20 | 0.57 |
| ▸ | CTSV | O60911 | 4/20 | 0.52 |
| ▸ | CTSL | P07711 | 4/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9672176 | 0.78 | MAOB (0.55) | MAOAMAOBCTSVCTSLMAPKAPK2 | |
| SCHEMBL11869773 | 0.73 | MAOB (1.00) | MAOAMAOBCTSVCTSLNSD2 | |
| SCHEMBL8316089 | 0.72 | MAPKAPK2 (0.55) | MAOAMAOBCTSVCTSLMAPKAPK2 | |
| SCHEMBL8316102 | 0.72 | MAPKAPK2 (0.55) | MAOAMAOBCTSVCTSLMAPKAPK2 | |
| SCHEMBL15536042 | 0.71 | CTSV (0.69) | MAOAMAOBCTSVCTSLALOX5 | |
| SCHEMBL18796679 | 0.71 | MAOA (0.62) | MAOAMAOBCTSVCTSLTRPM8 | |
| SCHEMBL6498712 | 0.70 | MAOA (0.52) | MAOAMAOBCTSVCTSLNSD2 | |
| SCHEMBL22487791 | 0.70 | MAOB (0.52) | MAOAMAOBCTSVCTSLCHEK1 | |
| SCHEMBL22541444 | 0.70 | CHEK1 (0.56) | MAOAMAOBCTSVCTSLNSD2 | |
| SCHEMBL31153237 | 0.70 | MCHR1 (0.61) | MAOAMAOBCTSVCTSLMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | claimed |
| US-7101903-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-09-05 | — | — | US | claimed |
| EP-1569639-A2 | SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050113436-A1 | 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis | WYETH (US) | 2005-05-26 | — | — | US | claimed |
| WO-2004052893-A2 | SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AND 3-OXOACETIC ACID SUBSTITUTED 2-HYDROXYMETHYLINDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | claimed |
| US-7459478-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | disclosed |
| US-20060270728-A1 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| US-7101903-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050113436-A1 | 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | SERPINE1, SERPINB1, SERPINC1 | MAOA 1848/4885MAOB 1418/4885CTSV 1499/4885 |
| US-20050113436-A1 | 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis | FGB, SERPINE1, MMP1 | MAOA 163/4885MAOB 66/4885CTSV 1596/4885 |
| US-20060270728-A1 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, TFPI, F2 | MAOA 268/4885MAOB 255/4885CTSV 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.